BACKGROUND: Lymphoproliferative disease is a common and serious complication of organ transplantation. It is well documented that the risk of its development increases with the level of immunosuppression. Less is known about its incidence, prevalence, timing, and prognosis. METHODS: The authors conducted a retrospective review of all patients with lymphoproliferative disease after renal transplantation documented in the Australia and New Zealand Dialysis and Transplant Registry from 1970 to March 2003. RESULTS: One hundred ninety-seven cases of lymphoproliferative disease occurred in 15,930 allografts in 13,516 recipients. There has been a steady increase in its incidence and prevalence each decade since 1970. Cases cluster into an early group (<2 years after transplantation) and a late group (5-10 years after transplantation). Risk factors include exposure to a calcineurin inhibitor, but there was no increased risk in those treated with anti-T-lymphocyte antibodies. Patient survival was poor: 51% at 1 year and 39% at 5 years. CONCLUSIONS: Lymphoproliferative disease is an increasingly common problem after renal transplantation, and the outcome is poor. Measures to reduce its incidence might include reduction of long-term immunosuppression exposure. Established disease has a high short-term mortality, and new treatment options, such as anti-B-lymphocyte monoclonal antibodies, should be aggressively pursued.
BACKGROUND:Lymphoproliferative disease is a common and serious complication of organ transplantation. It is well documented that the risk of its development increases with the level of immunosuppression. Less is known about its incidence, prevalence, timing, and prognosis. METHODS: The authors conducted a retrospective review of all patients with lymphoproliferative disease after renal transplantation documented in the Australia and New Zealand Dialysis and Transplant Registry from 1970 to March 2003. RESULTS: One hundred ninety-seven cases of lymphoproliferative disease occurred in 15,930 allografts in 13,516 recipients. There has been a steady increase in its incidence and prevalence each decade since 1970. Cases cluster into an early group (<2 years after transplantation) and a late group (5-10 years after transplantation). Risk factors include exposure to a calcineurin inhibitor, but there was no increased risk in those treated with anti-T-lymphocyte antibodies. Patient survival was poor: 51% at 1 year and 39% at 5 years. CONCLUSIONS:Lymphoproliferative disease is an increasingly common problem after renal transplantation, and the outcome is poor. Measures to reduce its incidence might include reduction of long-term immunosuppression exposure. Established disease has a high short-term mortality, and new treatment options, such as anti-B-lymphocyte monoclonal antibodies, should be aggressively pursued.
Authors: Robert P Carroll; David San Segundo; Kevin Hollowood; Teresa Marafioti; Taane G Clark; Paul N Harden; Kathryn J Wood Journal: J Am Soc Nephrol Date: 2010-01-28 Impact factor: 10.121
Authors: Scott C Quinlan; Lindsay M Morton; Ruth M Pfeiffer; Lesley A Anderson; Ola Landgren; Joan L Warren; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-04-20 Impact factor: 4.254
Authors: Andrew M Evens; Kevin A David; Irene Helenowski; Beverly Nelson; Dixon Kaufman; Sheetal M Kircher; Alla Gimelfarb; Elise Hattersley; Lauren A Mauro; Borko Jovanovic; Amy Chadburn; Patrick Stiff; Jane N Winter; Jayesh Mehta; Koen Van Besien; Stephanie Gregory; Leo I Gordon; Jamile M Shammo; Scott E Smith; Sonali M Smith Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544
Authors: A J Matas; K J Gillingham; A Humar; R Kandaswamy; D E R Sutherland; W D Payne; T B Dunn; J S Najarian Journal: Am J Transplant Date: 2008-11 Impact factor: 8.086